By highlighting the decreasing novel corona virus cases in the United States, a spokesperson for the Food and Drug Administration (FDA) of the United States said, the agency is going to be resuming the operations of the domestic surveillance inspection in the month of February 2022.
The Office of Regulatory Affairs of the US FDA said, on 2nd February 2022, the US FDA has decided to resume the domestic infections that are followed by the extended pause and the US FDA is going to be resuming conducting the domestic surveillance inspections across all the commodities along with the decrease in the novel corona virus cases across the United States.
The office also said that, the US FDA is going to be conducting the domestic and foreign inspection that are mission-critical and also using the US FDA’s alternative tools and the remote assessments for the purpose of providing the effective oversight of the drugs, foods, tobacco and medical products.
Shelly Burgess, senior media advisor within the Office of Regulatory Affairs of US FDA said the agency is also going to be continuing to proceed with the already planned foreign surveillance inspections that had now received the clearance of the country and they are also within the US CDC along with the recommendation of the corona virus travel.
The US FDA also said that, it is going to be suspending all but the domestic and foreign inspection through 19th January 2022 even though it is going to be re-assessing the plans that are needed.